In 2016, the agency implemented changes that allowed the use of mifepristone up to 10 weeks of pregnancy, rather than seven; reduced the number of required in-person visits for dispensing the drug from three to one; and allowed the drug to be prescribed by individuals like nurse practitioners.
An anti-abortion physicians' group argues that the FDA acted unlawfully when it relaxed restrictions on mifepristone, and they are pushing for reinstating stricter regulations surrounding the drug.
[
add
]
[
|
|
...
]